ReviewMolecular biology reports2026
Neutrophil extracellular traps in osteoporosis: mechanistic links to bone remodeling imbalance and therapeutic perspectives.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOsteoporosis (OP) is increasingly recognized as a disorder driven not only by endocrine and metabolic abnormalities but also by chronic low-grade inflammation and aging-related immune dysregulation. Neutrophil extracellular traps (NETs), web-like extracellular DNA-protein structures released by activated neutrophils, can act as structural inflammatory scaffolds that sustain sterile inflammation, oxidative injury, and microenvironmental imbalance. However, the mechanistic contribution and translational significance of NETs in osteoporosis remain incompletely integrated.
objectiveThis review aims to summarize the current evidence linking NET formation to bone remodeling imbalance in osteoporosis, with particular emphasis on osteoclast activation, osteoblast dysfunction, inflammaging, oxidative stress, ferroptosis, metabolic reprogramming, and potential NET-targeted therapeutic strategies.
methodsWe reviewed recent studies concerning NET biology, osteoimmunology, inflammaging, and inflammation-associated osteoporosis. Based on these findings, we constructed an integrated "NETs-inflammation-bone remodeling imbalance" framework to explain how persistent NET accumulation may promote osteoclastogenesis, impair osteogenic differentiation, amplify inflammatory feedback loops, and reshape the bone microenvironment. We also discussed the potential clinical relevance of neutrophil-related inflammatory indicators and NET-specific biomarkers.
conclusionPersistent NET formation and insufficient NET clearance under inflammaging conditions may contribute to a self-sustaining inflammatory-oxidative network in the bone microenvironment. NET-derived extracellular DNA, histones, neutrophil elastase, myeloperoxidase, and citrullinated proteins may activate pattern-recognition receptor pathways, including TLR4/NF-κB and potentially TLR9- and TLR2-related signaling, thereby enhancing RANKL-mediated osteoclastogenesis and suppressing osteoblast differentiation and survival. In parallel, NETs may amplify oxidative stress, disturb iron homeostasis, promote ferroptosis susceptibility, and induce metabolic reprogramming, collectively shifting bone remodeling toward bone resorption. Targeting NET formation, promoting NET degradation, or blocking NET-related inflammatory and oxidative signaling may provide new therapeutic opportunities for inflammation-driven osteoporosis. Nevertheless, the NETs-ferroptosis-metabolic reprogramming axis in osteoporosis should currently be regarded as a promising mechanistic framework that requires further experimental and clinical validation.
Indexed as
Identifiers
42340550What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.